Data di Pubblicazione:
2016
Abstract:
Concerns remain about the safety of adding long-acting β2-agonists to inhaled glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the Food and Drug Administration, we evaluated whether the addition of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with asthma.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Peters Stephen, P; Bleecker Eugene, R; Canonica, Giorgio; Park Yong, B; Ramirez, Ricardo; Hollis, Sally; Fjallbrant, Harald; Jorup, Carin; Martin Ubaldo, J
Link alla scheda completa:
Link al Full Text:
Pubblicato in: